Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of BioTelemetry Inc (NASDAQ:BEAT) in the 4th quarter, Holdings Channel reports. The firm acquired 4,393 shares of the medical research company’s stock, valued at approximately $262,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Meeder Asset Management Inc. acquired a new position in BioTelemetry during the fourth quarter valued at approximately $108,000. Loomis Sayles & Co. L P acquired a new position in BioTelemetry during the third quarter valued at approximately $23,211,000. Federated Investors Inc. PA raised its position in BioTelemetry by 8,359.7% during the third quarter. Federated Investors Inc. PA now owns 44,667 shares of the medical research company’s stock valued at $2,879,000 after purchasing an additional 44,139 shares in the last quarter. Logan Capital Management Inc. raised its position in BioTelemetry by 5.4% during the third quarter. Logan Capital Management Inc. now owns 52,524 shares of the medical research company’s stock valued at $3,385,000 after purchasing an additional 2,705 shares in the last quarter. Finally, Vanguard Group Inc raised its position in BioTelemetry by 2.8% during the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock valued at $122,462,000 after purchasing an additional 52,363 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

NASDAQ BEAT opened at $67.54 on Friday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 34.81 and a beta of 1.47. BioTelemetry Inc has a fifty-two week low of $29.85 and a fifty-two week high of $80.92. The company has a current ratio of 2.96, a quick ratio of 2.81 and a debt-to-equity ratio of 0.62.

BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Thursday, February 21st. The medical research company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.13. The firm had revenue of $103.60 million for the quarter, compared to analysts’ expectations of $102.84 million. BioTelemetry had a net margin of 10.72% and a return on equity of 24.46%. The company’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. As a group, sell-side analysts predict that BioTelemetry Inc will post 1.86 earnings per share for the current year.

In related news, VP Heather C. Getz sold 10,590 shares of the business’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $70.41, for a total value of $745,641.90. Following the sale, the vice president now owns 80,661 shares of the company’s stock, valued at $5,679,341.01. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Heather C. Getz sold 8,236 shares of the business’s stock in a transaction on Thursday, January 17th. The stock was sold at an average price of $70.01, for a total transaction of $576,602.36. Following the completion of the sale, the vice president now directly owns 88,797 shares in the company, valued at approximately $6,216,677.97. The disclosure for this sale can be found here. In the last three months, insiders sold 177,198 shares of company stock worth $12,419,736. 8.30% of the stock is currently owned by insiders.

Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. ValuEngine cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 23rd. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 18th. Lake Street Capital set a $90.00 target price on shares of BioTelemetry and gave the stock a “buy” rating in a research note on Friday, February 22nd. Finally, Sidoti set a $95.00 target price on shares of BioTelemetry and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $75.67.

ILLEGAL ACTIVITY WARNING: “4,393 Shares in BioTelemetry Inc (BEAT) Acquired by Los Angeles Capital Management & Equity Research Inc.” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/4393-shares-in-biotelemetry-inc-beat-acquired-by-los-angeles-capital-management-equity-research-inc/2897481.html.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Featured Story: What is a stock split?

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.